SCHEMBL6651476

SCHEMBL6651476

NC(=O)c1ccc(-c2ccc(Cl)c(Cl)c2)nc1N1CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.42
PIM3 Q86V86 2/20 0.42
ADRB1 P08588 1/20 0.42
PARP1 P09874 2/20 0.41
PARP2 Q9UGN5 2/20 0.41
PRKD1 Q15139 5/20 0.41
PRKD2 Q9BZL6 4/20 0.41
PIM2 Q9P1W9 1/20 0.40
ACVR1 Q04771 3/20 0.40
PRKD3 O94806 1/20 0.40
CDC7 O00311 1/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
CDK2 P24941 1/20 0.39
GSK3B P49841 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
DYRK1A Q13627 1/20 0.39
TGFBR1 P36897 2/20 0.39
EIF4E P06730 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6629433 0.82 ADORA3 (0.43) PIM1PIM3ADRB1PARP1PARP2
SCHEMBL6651477 0.82 ADRB1 (0.47) PIM1PIM3ADRB1PRKD1PIM2
SCHEMBL7984894 0.74 PARP1 (0.40) PARP1PRKD1PRKD2ACVR1PRKD3
SCHEMBL1579504 0.73 PRKD1 (0.69) ADRB1PRKD1PRKD2PRKCAPRKCD
SCHEMBL3918629 0.72 ABL1 (0.42) ADRB1CLK4DYRK1A
SCHEMBL3453077 0.70 ADRB1 (0.48) ADRB1PARP1ACVR1IRAK4JAK2
SCHEMBL16613201 0.68 ADRB2 (0.52) ADRB1PARP1PRKD1PRKD2PRKD3
SCHEMBL3319564 0.68 ADRB1 (0.51) PIM1ADRB1CDC7CLK4
SCHEMBL6629435 0.68 ADORA3 (0.46) ADRB1ACVR1ROCK2CLK4IRAK4
SCHEMBL16597825 0.68 BTK (0.48) ADRB1IRAK4PRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 EP disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP PIM1 787/4885PIM3 1180/4885ADRB1 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.